$FENC
FENNEC PHARMACEUTICALS INC.

2016 Q2 Form 10-Q Financial Statement

#000114420417042911 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2016 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $570.0K
YoY Change 14.0%
% of Gross Profit
Research & Development $139.0K
YoY Change 157.41%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $139.0K
YoY Change 157.41%
Operating Profit -$707.0K
YoY Change
Interest Expense -$10.00K
YoY Change -102.56%
% of Operating Profit
Other Income/Expense, Net -$17.00K
YoY Change -104.52%
Pretax Income -$720.0K
YoY Change 323.53%
Income Tax
% Of Pretax Income
Net Earnings -$724.0K
YoY Change 318.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$0.06
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.080M
YoY Change 174.59%
Cash & Equivalents $5.081M
Short-Term Investments
Other Short-Term Assets $30.00K
YoY Change 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.100M
YoY Change 172.73%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.100M
Total Long-Term Assets $0.00
Total Assets $5.100M
YoY Change 172.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $350.0K
YoY Change -12.5%
Accrued Expenses $50.00K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $450.0K
YoY Change -40.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $450.0K
Total Long-Term Liabilities $0.00
Total Liabilities $450.0K
YoY Change -40.79%
SHAREHOLDERS EQUITY
Retained Earnings $113.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.653M
YoY Change
Total Liabilities & Shareholders Equity $5.100M
YoY Change 172.73%

Cashflow Statement

Concept 2016 Q2
OPERATING ACTIVITIES
Net Income -$724.0K
YoY Change 318.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$470.0K
YoY Change -8.02%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.010M
YoY Change 1015.81%
NET CHANGE
Cash From Operating Activities -470.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 5.010M
Net Change In Cash 4.540M
YoY Change -7422.58%
FREE CASH FLOW
Cash From Operating Activities -$470.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1692000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
975000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2250000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1161000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-157000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
26000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2404000 USD
us-gaap Net Income Loss
NetIncomeLoss
-1144000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
558000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
186000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11873000 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13917000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11873000 shares
CY2017Q2 us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Revenues
Revenues
0 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1146000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
568000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1479000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-707000 USD
CY2017Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-120000 USD
CY2016Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-17000 USD
CY2017Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
5000 USD
CY2016Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-119000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1598000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
333000 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14192000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12813000 shares
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
342000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
30000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
502000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
111000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1363000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-969000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6306000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4139000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5081000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7669000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5108000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
52000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-31000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
98000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
108000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-22000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-58000 USD
CY2017Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
286000 USD
CY2016Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
17000 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
461000 USD
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
111000 USD
CY2017Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-688000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-470000 USD
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
98000 USD
CY2016Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6000 USD
CY2017Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-11000 USD
CY2016Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-22000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-806000 USD
CY2017Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98000 USD
CY2017Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7571000 USD
CY2017Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
10232000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3926000 USD
CY2017Q2 us-gaap Cash
Cash
127000 USD
CY2016Q4 us-gaap Cash
Cash
51000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13917000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11873000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016Q4 fencf Stock Options Issuance
StockOptionsIssuance
40000 shares
fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
1000 shares
fencf Stock Options Issuance Forfeited
StockOptionsIssuanceForfeited
0 shares
fencf Stock Options Issuance Expired
StockOptionsIssuanceExpired
0 shares
CY2017Q2 fencf Stock Options Issuance
StockOptionsIssuance
39000 shares
CY2016Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.81
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.89
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017Q2 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.8
CY2017Q1 fencf Stock Options Issuance
StockOptionsIssuance
40000 shares
CY2017Q2 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
1000 shares
CY2017Q2 fencf Stock Options Issuance Forfeited
StockOptionsIssuanceForfeited
0 shares
CY2017Q2 fencf Stock Options Issuance Expired
StockOptionsIssuanceExpired
0 shares
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10232000 USD
CY2017Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
190000 USD
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1383000 shares
us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
342000 USD
us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
30000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
844000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
141000 USD
CY2017Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
286000 USD
CY2016Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
17000 USD
CY2017Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
747000 USD
CY2016Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
128000 USD
fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
FENCF
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15630663000 shares
CY2017Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15629000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13643000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15629000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13643000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of estimates</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period.&#160;Actual results could differ from those estimates.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company&#8217;s financial position at June 30, 2017 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2017 included estimates necessary to value derivative instruments, disclosed in Note 4.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2 us-gaap Cash
Cash
67000 CAD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q2 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1000 USD
CY2016Q2 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0151 pure
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.37 pure
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7571000 USD
CY2016Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5000000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7571000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5000000 USD
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0110 pure
fencf Shareholders Rights Plan Agreement Description
ShareholdersRightsPlanAgreementDescription
On June 27, 2017, the Company&#8217;s shareholders approved a Shareholder Rights Plan Agreement (the &#34;Rights Plan&#34;) for the Company. The Rights Plan is to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or other acquisition of control of the Corporation. The Rights Plan is designed to require any potential transaction that will result in a person owning, in the aggregate, 20% or more of the outstanding Common Shares to be structured as a formal take-over bid that satisfies certain minimum requirements relating primarily to the manner in which the bid must be made, the minimum number of days the bid must remain open, and the minimum number of shares that must be acquired under the bid.
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36000 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000 CAD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
49000 shares
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
2861000 USD

Files In Submission

Name View Source Status
0001144204-17-042911-index-headers.html Edgar Link pending
0001144204-17-042911-index.html Edgar Link pending
0001144204-17-042911.txt Edgar Link pending
0001144204-17-042911-xbrl.zip Edgar Link pending
fencf-20170630.xml Edgar Link completed
fencf-20170630.xsd Edgar Link pending
fencf-20170630_cal.xml Edgar Link unprocessable
fencf-20170630_def.xml Edgar Link unprocessable
fencf-20170630_lab.xml Edgar Link unprocessable
fencf-20170630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v472519_10q.htm Edgar Link pending
v472519_ex31-1.htm Edgar Link pending
v472519_ex31-2.htm Edgar Link pending
v472519_ex32-1.htm Edgar Link pending
v472519_ex99-1.htm Edgar Link pending
v472519_ex99-1img1.jpg Edgar Link pending